Effect of rhTPO in the treatment of thrombocytopenia after CHOP chemotherapy

A single center clinical observation for preventive rhTPO treatment of thrombocytopenia after chemotherapy for invasive lymphoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019725

Enrollment

Unknown

Registered

2018-11-25

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

Group 1:rhTPO

Group 2:rhIL-11

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged = 18 years old; Pathologic diagnosis was found to be malignant invasive non-Hodgkin lymphoma; Can tolerate conventional treatment; ECOG = 2 points; The survival period is more than 3 months; Pregnancy test negative for female patients; The patient voluntarily participates and signs an informed consent form;

Exclusion criteria

Exclusion criteria: People with a history of severe thrombosis; People who are allergic to rhIL-11 or rhTPO; Breastfeeding and pregnant women; Are participating in clinical trials of other new drugs;

Design outcomes

Primary

Measure	Time frame
platelet count;	—

Countries

China

Contacts

Public ContactZhang Xian

Dalian Medical University Affiliated Second Hospital

17709873632@163.com+86 17709873632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026